<DOC>
	<DOCNO>NCT02477696</DOCNO>
	<brief_summary>This study design evaluate PFS endpoint acalabrutinib v ibrutinib previously treat chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Elevate CLL R/R : Study Acalabrutinib ( ACP-196 ) Versus Ibrutinib Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Men woman ≥ 18 year age . ECOG performance status 0 2 . Diagnosis CLL . Must ≥ 1 follow highrisk prognostic factor : Presence 17p del central laboratory . Presence 11q del central laboratory . Active disease meeting ≥ 1 follow IWCLL 2008 criterion require treatment Must receive ≥ 1 prior therapy CLL . Meet follow laboratory parameter : ANC ≥ 750 cells/μL ≥ 500 cells/μL subject document bone marrow involvement , independent growth factor support 7 day assessment . Platelet count ≥ 30,000 cells/μL without transfusion support 7 day assessment . Subjects transfusiondependent thrombocytopenia exclude . Serum AST/SGOT ALT/SGPT ≤ 3.0 x ULN . Total bilirubin ≤ 1.5 x ULN . Estimated creatinine clearance ≥ 30 mL/min . Known CNS lymphoma leukemia . Known prolymphocytic leukemia history , currently suspect , Richter 's syndrome . Uncontrolled autoimmune hemolytic anemia idiopathic thrombocytopenia purpura . Prior exposure ibrutinib BCR inhibitor BCL2 inhibitor . Received chemotherapy , external beam radiation therapy , anticancer antibody , investigational drug within 30 day first dose study drug . Prior radio toxinconjugated antibody therapy . Prior allogeneic stem cell autologous transplant . Major surgery within 4 week first dose study drug . Prior malignancy , except adequately treat lentigo maligna melanoma , nonmelanomatous skin cancer , situ cervical carcinoma malignancy treat evidence active disease &gt; 3 year Screening low risk recurrence . Significant cardiovascular disease within 6 month screen . Known history infection HIV . History stroke intracranial hemorrhage within 6 month randomization . History bleed diathesis . Requires receive anticoagulation warfarin equivalent vitamin K antagonists within 7 day first dose study drug . Requires treatment strong CYP3A inhibitor/inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>